iXCells Biotechnologies and Rosebud Biosciences recently announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare diseases. As iXCells enters its next phase of growth, the collaboration expands the Company’s custom integrated platform and strengthens the suite of modeling technologies available to customers seeking advanced predictive and physiologically relevant systems.

Through this partnership, iXCells will integrate Rosebud’s organoid generation and characterization expertise into its existing iPSC solutions, enabling access to complex 3D human systems that better represent tissue-level biology and simulate therapeutic response. The combined workflow brings together iXCells’ scalable, modular iPSC platform, iPSCore, with Rosebud’s AI-driven organoid platform, designed to generate scalable, reproducible human tissue data for drug discovery and safety assessment. Together, the technologies offer researchers more complete and biologically representative model systems for understanding disease mechanisms and drug safety.

The expansion of organoid capabilities reflects iXCells’ continued investment in next-generation modeling technologies that meet growing customer demand for human-relevant and predictive systems. Organoids are an essential component of translational research strategies, particularly for evaluating drug toxicity and tissue-specific responses. This integrated offering delivers the consistency, scalability, and reproducibility required for screening, engineering, multi-omics profiling, and mechanism-of-action studies within a unified, end-to-end solution.

Steve Smith, Chief Executive Officer of iXCells Biotechnologies, commented: “Our focus has always been on anticipating what our partners will need next, and Rosebud brings impressive depth in organoid science that aligns perfectly with that vision. This collaboration enhances our end-to-end platform and expands our ability to deliver next-generation models that reflect human biology with greater depth and accuracy. In areas such as rare diseases, where predicting human-specific safety and response earlier can significantly impact development timelines and patient outcomes, these integrated systems provide critical insight. This partnership reflects the strategic direction we are taking as iXCells scales its platform to support more complex, translationally focused programs for our partners.”

Kitch Wilson, Chief Executive Officer and Co-Founder, Rosebud Biosciences, added: “Our partnership with iXCells allows us to make advanced organoid systems more accessible to researchers who need models that better represent human biology. By combining our complementary strengths, we can support deeper exploration of disease biology and help drive the next generation of therapeutic discovery.”

iXCells Biotechnologies is a leading San Diego, CA-based cell technology company focused on generating a wide variety of predictive human disease models. In addition, iXCells is pursuing custom and patient-specific services leveraging its expertise in the preparation, handling, engineering and differentiation of induced pluripotent stem cells (iPSCs) and in the isolation of primary cells along with associated services for descriptive and functional cell characterization, compound screening and toxicology testing.

The company’s mission is to supply a diverse range of human disease models, derived from ethically sourced patient and healthy donor tissues, to support academic, pharmaceutical, and clinical researchers globally. By providing predictive human cell models, we aim to deepen the understanding of the molecular mechanisms underlying disease onset and progression as much as slow-down or reversion of disease, and accelerate the discovery and development of new medicines and innovative therapies to further advance precision medicine. For more information please visit: https://ixcellsbiotech.com/.

Rosebud Biosciences builds industrialized, AI-powered human organoid platforms for drug discovery, toxicology, and precision medicine. The company integrates automated organoid differentiation, scalable robotics-driven workflows, and advanced machine learning analysis to generate large volumes of standardized, clinically meaningful human data. Capable of growing 10k organoids simultaneously with plans for multiples of 10k, Rosebud’s automation- and AI-first approach enables reproducible, high throughput evaluation of drug safety and efficacy across multiple human organ systems. The platform delivers the predictive, patient specific insights envisioned by FDA aligned NAMs, providing faster and more accurate assessments of how human tissues respond to therapeutic compounds. The company was founded by experts in stem cell biology, organoid engineering, and AI-driven phenotyping, bringing deep scientific pedigree to the creation of next generation human-based models. For more information, visit https://rosebudbiosci.com/.